Ubrogepant
- Generic Name
- Ubrogepant
- Brand Names
- Ubrelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26F3N5O3
- CAS Number
- 1374248-77-7
- Unique Ingredient Identifier
- AD0O8X2QJR
- Background
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of med...
- Indication
Ubrogepant is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
AbbVie (NYSE: ABBV), Realty Income (NYSE: O), and Verizon Communications (NYSE: VZ) are recommended for long-term passive income due to their consistent dividend growth and strong financial positions.
AbbVie's $9B bet collapses as closely watched schizophrenia drug fails studies
AbbVie lost $40 billion in market value after its experimental drug emraclidine failed two clinical trials for schizophrenia. Despite the setback, AbbVie remains focused on neuroscience and has a diverse portfolio of brain medicines. The failure of emraclidine removes a competitive threat for Bristol Myers' Cobenfy, an approved antipsychotic.
AbbVie faulted for misleading ad featuring Serena Williams
FDA criticizes AbbVie's Ubrelvy ad featuring Serena Williams for overstating drug's efficacy, demanding immediate ad halt or Ubrelvy distribution stop. AbbVie halts ad airing and complies with FDA investigation.
Migraine Drug Ubrelvy May Stop Headaches Before They Start
Ubrelvy (ubrogepant) showed 73% more effectiveness in reducing migraine disability within 2 hours compared to placebo in a clinical trial, potentially improving quality of life for migraine sufferers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath